N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• RAS oncogenic mutations are prevalent in human cancers.
• Targeting RAS proteins has been challenging due to their complex biology.
• RAS protein function is dependent on lipid modifications and influences cellular lipid metabolism.

Purpose of the Study:

• To identify novel pharmacological agents that block RAS oncogenic signaling through a distinct mechanism.
• To screen a bioactive lipid library for compounds inhibiting RAS transformation.
• To characterize the mechanism of action of newly discovered RAS inhibitors.

Main Methods:

• Screening of a bioactive lipid library using a RAS-specific cell viability assay.
• Assessing the inhibitory effects of NADA on NRAS and KRAS transformation and signaling.
• Investigating the effect of NADA on RAS protein plasma membrane translocation.
• Analyzing the impact of NADA on NRAS palmitoylation and subcellular localization.

Main Results:

• Discovery of a new class of RAS transformation inhibitors, exemplified by N-arachidonoyl dopamine (NADA).
• NADA inhibits NRAS transformation and signaling more effectively than KRAS4B.
• NADA blocks the plasma membrane translocation of NRAS and KRAS4A, but not KRAS4B.
• NADA induces NRAS redistribution to the Golgi apparatus in a palmitoylation-dependent manner.

Conclusions:

• NADA represents a novel class of inhibitors targeting RAS oncogenic signaling.
• NADA inhibits NRAS and KRAS4A plasma membrane translocation via a novel molecular mechanism.
• These findings provide a basis for developing new targeted therapies for various human cancers.